SOUTH SAN FRANCISCO, Calif. / Aug 29, 2025 / Business Wire / Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time.
A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).
| Last Trade: | US$44.36 |
| Daily Change: | -0.25 -0.56 |
| Daily Volume: | 639,947 |
| Market Cap: | US$3.510B |
November 04, 2025 November 03, 2025 September 28, 2025 September 24, 2025 September 09, 2025 | |

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load